TaiGen Biopharmaceuticals Holdings Limited
4157
Rank in Stocks
#17250
TaiGen Biopharmaceuticals Holdings Limited is a global pharmaceutical firm... TaiGen Biopharmaceuticals Holdings Limited is a global pharmaceutical firm dedicated to pioneering innovative treatments for life-altering diseases. Its robust development pipeline features several key assets. Among these is Taigexyn (Nemonoxacin), a non-fluorinated quinolone antibiotic currently being advanced for the treatment of various bacterial infections, including community-acquired pneumonia and diabetic foot infections. The company is also progressing Burixafor, a stem cell mobilizer with applications in stem cell transplantation and chemosensitization. Further contributing to its portfolio is TG-1000, an antiviral medication designed to combat influenza A, B, and the avian influenza H7N9 strain. Additionally, Furaprevir, a hepatitis C virus (HCV) protease inhibitor, is under development for managing chronic hepatitis C. Established in 2001, TaiGen Biopharmaceuticals maintains its headquarters in Taipei City, Taiwan.
Share Price
$0.24661927
Last synced: 2026-11-10
Market Cap
$175.55M
Change (1 day)
-0.49%
Change (1 year)
-16.37%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade TaiGen Biopharmaceuticals Holdings Limited (4157)
Category
Healthcare
Operating Margin for TaiGen Biopharmaceuticals Holdings Limited (4157)
Operating Margin as of November 2026 TTM: 32.24%
According to TaiGen Biopharmaceuticals Holdings Limited's latest financial reports, its current operating margin (TTM) is 32.24%. At the end of 2025 the company had an operating margin of 26.74%.
Operating Margin history for TaiGen Biopharmaceuticals Holdings Limited from 2010 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | 32.24% | 20.57% |
| 2025 | 26.74% | -132.99% |
| 2024 | -81.05% | -42.87% |
| 2023 | -141.88% | -76.33% |
| 2022 | -599.37% | -985.46% |
| 2021 | 67.69% | -103.93% |
| 2020 | -1,723.95% | 22.01% |
| 2019 | -1,412.99% | 61.96% |
| 2018 | -872.43% | -1,953.08% |
| 2017 | 47.08% | -128.92% |
| 2016 | -162.79% | -70.55% |
| 2015 | -552.80% | 41.51% |
| 2014 | -390.63% | -45.03% |
| 2013 | -710.67% | -42.09% |
| 2012 | -1,227.11% | 1,183.05% |
| 2011 | -95.64% | -96.84% |
| 2010 | -3,026.19% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | -98.80% |
US
|
|
| -149.01% | -104.62% |
US
|
|
| 25.57% | -99.21% |
AU
|
|
| 31.23% | -99.03% |
BE
|
|
| 29.35% | -99.09% |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about TaiGen Biopharmaceuticals Holdings Limited's operating margin
What is TaiGen Biopharmaceuticals Holdings Limited's operating margin?
TaiGen Biopharmaceuticals Holdings Limited's operating margin is 32.24%, as of Nov 2026.
What was TaiGen Biopharmaceuticals Holdings Limited's operating margin in 2025?
In 2025, TaiGen Biopharmaceuticals Holdings Limited's operating margin was 26.74%, compared with -81.05% in 2024.
How has TaiGen Biopharmaceuticals Holdings Limited's operating margin changed since 2020?
From 2020 to 2025, TaiGen Biopharmaceuticals Holdings Limited's operating margin was highest in 2021 (67.69%) and lowest in 2020 (-1,723.95%).
How does TaiGen Biopharmaceuticals Holdings Limited's operating margin compare with similar companies?
TaiGen Biopharmaceuticals Holdings Limited's operating margin (32.24%) is higher than that of 4 of the 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.